Syncom Formul. Share Price & Earnings Call Analysis

Financials of Syncom Formul.

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Syncom Formul.

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +615962637387101127148117121115134
Expenses +5553565764769011213110110393113
Operating Profit666791012151716192121
OPM %10%10%10%11%12%12%12%11%12%14%15%18%16%
Other Income +72443144765514
Interest1111100000000
Depreciation1111111111112
Profit before tax1068991015172320222533
Tax %18%27%24%25%27%24%25%24%24%22%25%25%25%
Net Profit +84667811131816171925
EPS in Rs0.090.050.070.070.070.080.120.140.190.170.180.200.26

Financials of Syncom Formul.

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +173184185159187206245216222257461487
Expenses +155167168147175189207196202229407409
Operating Profit181716121217382020285477
OPM %11%9%9%7%6%8%16%9%9%11%12%16%
Other Income +13345571215131731
Interest000001023511
Depreciation333444445557
Profit before tax1616161213174126273265101
Tax %38%36%33%28%12%18%28%24%24%26%24%24%
Net Profit +10101191114292020244976
EPS in Rs0.130.130.140.110.140.180.370.230.210.250.520.81
Dividend Payout %16%15%15%0%0%0%0%13%0%0%0%0%

Financials of Syncom Formul.

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital787878787878798694949494
Reserves223136445568109136162192246318
Borrowings +661212926258837241
Other Liabilities +3161483732334228383366116
Total Liabilities138175175171173181292308377392410529
Fixed Assets +464685898993919491120125184
CWIP0501000626000
Investments62312211143646693109
Other Assets +8510189798387189165196206192237
Total Assets138175175171173181292308377392410529

Financials of Syncom Formul.

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +02417-246-21610-62358
Cash from Investing Activity +1-23-8-222-75-27-4584-18-51
Cash from Financing Activity +1-2-2-2-0-772835-15-68-3
Net Cash Flow2-16-671-5-2163-634
Free Cash Flow-3169-8104-55-10-141347
CFO/OP32%176%128%13%66%61%24%113%86%6%70%105%

Financials of Syncom Formul.

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days6691918781771121141241328581
Inventory Days344329373739515153494981
Days Payable6313092755749663652335196
Cash Conversion Cycle37427496167961291241488366
Working Capital Days8440457574882833-45195164
ROCE %16%15%14%9%9%12%21%11%10%10%19%27%

Others in Pharmaceuticals & Biotechnology this season

  • Novartis India Ltd (Q1 FY27)

    Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…

  • IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab Ltd (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharmaceuticals Ltd (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd